NASDAQ · ELUT
Elutia Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ELUT: Nov 05, 2026
Elutia Inc. Class A Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. The reported EPS for the same quarter last year was $-0.01.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · RTTNews · Fintel · Zacks- The Motley Fool · Aug 20, 4:58 PM EDTElutia (ELUT) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 18, 1:27 PM EDTElutia Completes $11 Mln SimpliDerm Sale As Company Sharpens Focus On NXT-41x(RTTNews) – Elutia Inc. (ELUT), a drug-eluting biomatrix company, has completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics for total consideration of up to $11 million, including $8 million at closing and up to $3 million in milestone
- RTTNews · Jul 18, 1:19 AM EDTWeekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data(RTTNews) – This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and regulatory setbacks.
- RTTNews · Jul 17, 4:50 AM EDTElutia Signs Agreement To Sell SimpliDerm Business To Cellution For Up To $11 Mln; Stock Down(RTTNews) – Elutia Inc. (ELUT) announced the signing of a definitive agreement to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics Inc. for total consideration of up to $11 million.
- The Motley Fool · May 15, 8:58 AM EDTElutia (ELUT) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Mar 27, 1:44 PM EDTElutia (ELUT) Price Target Increased by 42.86% to 5.10The average one-year price target for Elutia (NasdaqCM:ELUT) has been revised to $5.10 / share. This is an increase of 42.86% from the prior estimate of $3.57 dated February 21, 2026. The price target is an average of many targets provided by analysts. The lat
- The Motley Fool · Mar 11, 6:47 PM EDTElutia (ELUT) Q4 2025 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Jan 14, 10:41 PM ESTPlus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance(RTTNews) – Biotech and healthcare names were among the notable movers in Wednesday's after-hours trading session, with several small-cap companies posting strong gains on the back of corporate updates and investor momentum.
- Zacks · Dec 31, 12:00 PM ESTELUTIA INC (ELUT) Upgraded to Buy: Here's What You Should KnowELUTIA INC (ELUT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- RTTNews · Dec 21, 11:20 PM ESTFriday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength(RTTNews) – Several biotechnology and life sciences companies posted notable gains in after-hours trading on Friday, reflecting investor interest in recent clinical and corporate developments.
- RTTNews · Dec 16, 11:29 PM ESTAfter-Hours Gainers: A Quiet Session With A Standout Biotech Surge(RTTNews) – The after-hours market delivered a mixed but generally positive tone on Tuesday evening, with several small- and mid-cap names posting modest gains. One biotech, however, stole the spotlight with a dramatic surge following major clinical news.
- RTTNews · Sep 17, 12:40 AM EDTBiotechs Rally After Hours On Trial Progress, Funding Moves, And Upcoming Milestones(RTTNews) – Several biotech names posted notable after-hours gains on Tuesday, driven by clinical trial updates, fresh funding announcements, and upcoming product showcases. From gene editing breakthroughs to Alzheimer's trial enrollment, here's a quick look at the latest movers
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Elutia Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.